首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1712514

全球肿瘤治疗市场 - 2025-2033

Global Oncology Therapy Market - 2025-2033

出版日期: 2025年04月22日 | 出版商:

DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球肿瘤治疗市场规模达1,939.8亿美元，预计2033年将达到4,402.6亿美元，在2025-2033年的预测期内，年复合成长率（CAGR）为9.6%。

肿瘤治疗是指旨在管理和治疗癌症的医疗治疗和介入。它涵盖了广泛的治疗策略，旨在消除或控制癌细胞、缓解症状、提高患者的生活质量，并最终在可能的情况下实现缓解或治癒。肿瘤治疗是多学科的，通常需要结合多种治疗、个人化治疗和持续监测。

肿瘤治疗是一个广泛且不断发展的领域，旨在透过各种方法治疗癌症，包括化疗、免疫疗法、标靶疗法、手术和放射治疗。这些疗法可以组合使用或单独使用，这取决于癌症的类型和阶段。随着个人化医疗的进步，肿瘤治疗的未来在于更精确、更有针对性的治疗，以提供更高的疗效和更少的副作用。

市场动态：

驾驶员和约束装置

癌症发生率的上升显着推动了肿瘤治疗市场的成长

癌症在全球范围内变得越来越常见，其发病率的增加使得对有效治疗和疗法的需求日益增加。随着癌症病例的增加，对各种肿瘤疗法的需求也日益增长，例如化疗、免疫疗法、标靶疗法和放射疗法。越来越多的人被诊断出患有癌症，需要治疗的患者数量也随之增加，导致对现有和新型癌症疗法的需求增加。

例如，根据美国国立卫生研究院的数据，癌症是全球主要死亡原因之一。 2022年，全球新增癌症病例近2,000万，癌症死亡人数达970万。到2040年，预计每年新发癌症病例数将增加至2,990万，癌症死亡人数将增加至1,530万人。根据国际癌症研究机构的预测，2025年全球癌症发生人数将达2,130万，2030年全球癌症发生人数预计将达2,410万。

乳癌正成为世界上最严重的癌症，发生率和盛行率呈现惊人上升趋势。例如，根据国际癌症研究机构的预测，预计到 2030 年，全球乳癌发病病例将从 2022 年的 230 万例增加到近 270 万例。随着越来越多的人被诊断出患有癌症，对从化疗到先进免疫疗法等有效癌症治疗的需求日益增加，确保市场持续扩张。

各种肿瘤治疗相关的不良反应阻碍了市场成长

虽然肿瘤疗法对于癌症治疗至关重要，但这些疗法的不良反应可能会阻碍其广泛应用和市场成长。副作用从轻微到严重不等，通常会影响患者的生活质量，并可能导致治疗中断或改变。这些不良影响的存在给医疗保健提供者、製药公司和患者带来了挑战，影响了治疗决策并限制了市场的潜在成长。

化疗是最常见的癌症治疗方法之一，但由于其对快速分裂细胞的非选择性作用，因此会产生多种副作用。它不仅针对癌细胞，还会影响正常健康细胞，导致严重的副作用。这些副作用可能导致治疗延迟或剂量减少，进而影响治疗的整体效果和患者的依从性。因此，患者可能会寻求替代疗法或选择不完成规定的化疗方案，阻碍整体市场的成长。

免疫疗法虽然在治疗黑色素瘤和肺癌等癌症方面具有革命性，但也带来了一系列独特的免疫相关不良事件。这些不良影响源自于免疫系统对癌症治疗的过度反应，这会导致正常组织和器官出现发炎。标靶治疗虽然比传统化疗更精确，但仍会产生与其影响的标靶分子相关的特定副作用。这些疗法对于由特定基因突变引起的癌症非常有效，但与抑制这些分子标靶相关的副作用可能会限制它们的使用。

市场领导者和先驱者
- 新兴先锋和杰出参与者
- 拥有最大行销品牌的既定领导者
- 拥有成熟产品的市场领导者
最新进展与突破
监管和报销情况
- 北美洲
- 欧洲
- 亚太地区
- 南美洲
- 中东和非洲
波特五力分析
专利分析
SWOT分析
未满足的需求和差距
市场进入和扩张的推荐策略
情境分析：最佳情况、基本情况和最坏情况预测
定价分析和价格动态

第五章：肿瘤治疗市场（依疗法划分）

化疗
- 烷化剂
- 抗代谢药
- 抗肿瘤抗生素
- 拓朴异构酶抑制剂
- 其他的
标靶治疗
- 单株抗体
- 小分子抑制剂
免疫疗法
- 免疫检查点抑制剂（PD-1、PD-L1、CTLA-4）
- CAR-T细胞疗法
- 癌症疫苗
- 细胞因子
- 其他的
荷尔蒙疗法
- 抗雌激素
- 芳香化酶抑制剂
- 黄体生成素释放激素 (LHRH) 激动剂/拮抗剂
- 其他的
放射治疗
其他的

第六章：肿瘤治疗市场（依应用）

乳癌
肺癌
血癌
摄护腺癌
大肠直肠癌
胃癌
肝癌
食道癌
子宫颈癌
卵巢癌
膀胱癌
头颈癌
皮肤癌（黑色素瘤）
胰腺癌
肾癌
其他的

第七章：肿瘤治疗市场（依最终使用者划分）

医院
癌症研究中心
专科诊所
其他的

第八章：肿瘤治疗市场，依区域市场分析与成长机会

北美洲
- 我们
- 加拿大
- 墨西哥
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
南美洲
- 巴西
- 阿根廷
- 南美洲其他地区
中东和非洲

第九章：竞争格局与市场定位

竞争概况和主要市场参与者
市占率分析与定位矩阵
策略伙伴关係、併购
产品组合和创新的关键发展
公司基准化分析

第十章：公司简介

Amgen Inc.

公司概况
产品组合
- 产品描述
- 产品关键绩效指标 (KPI)
- 历史和预测产品销售
- 产品销售量
财务概览
- 公司收入
- 地区收入份额
- 收入预测
关键进展
- 併购
- 关键产品开发活动
- 监管部门批准等
SWOT分析

AstraZeneca
Bayer AG
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd
Novartis AG
GSK plc
Eli Lilly and Company
Rigel Pharmaceuticals, Inc.

第 11 章：假设与研究方法

资料收集方法
数据三角测量
预测技术
数据验证和确认

第 12 章：附录

简介目录

Product Code: PH1793

The global oncology therapy market size reached US$ 193.98 billion in 2024 and is expected to reach US$ 440.26 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025-2033.

Oncology therapy refers to the medical treatments and interventions designed to manage and treat cancer. It encompasses a wide range of therapeutic strategies aimed at eliminating or controlling cancer cells, alleviating symptoms, enhancing the patient's quality of life, and ultimately achieving remission or a cure, where possible. Oncology therapy is multi-disciplinary and often requires a combination of treatments, personalized approaches, and ongoing monitoring.

Oncology therapy is a broad and evolving field that aims to treat cancer through various approaches, including chemotherapy, immunotherapy, targeted therapy, surgery, and radiation. These therapies can be used in combination or alone, depending on the type and stage of cancer. With advances in personalized medicine, the future of oncology therapy lies in more precise and tailored treatments that offer higher effectiveness with fewer side effects.

Market Dynamics: Drivers & Restraints

The rising prevalence of cancer is significantly driving the oncology therapy market growth

Cancer is becoming more common globally, and its increasing incidence is creating a heightened demand for effective treatments and therapies. As cancer cases rise, there is a growing need for various oncology therapies, such as chemotherapy, immunotherapy, targeted therapy, and radiation. More people are being diagnosed with cancer, increasing the patient pool requiring treatment, leading to greater demand for both established and novel cancer therapies.

For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. According to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.

Breast cancer is becoming the most burdensome cancer in the world, with an alarming rise in incidence and prevalence rate. For instance, according to the International Agency for Research on Cancer projections, nearly 2.7 million breast cancer incidence cases are expected to be reported in 2030, rising from 2.3 million in 2022. With more people being diagnosed, the demand for effective cancer treatments, ranging from chemotherapy to advanced immunotherapies, is intensifying, ensuring continued expansion in the market.

Adverse effects associated with various oncology therapies hamper market growth

While oncology therapies are essential for cancer treatment, adverse effects associated with these therapies can hamper their widespread adoption and market growth. The side effects, which range from mild to severe, often affect patients' quality of life and can lead to treatment discontinuation or modification. The presence of these adverse effects poses challenges for healthcare providers, pharmaceutical companies, and patients, influencing treatment decisions and limiting the market's potential growth.

Chemotherapy is one of the most common cancer treatments, but it is associated with a wide range of toxic side effects due to its non-selective action on rapidly dividing cells. It not only targets cancer cells but also affects normal, healthy cells, leading to significant side effects. These side effects can lead to treatment delays or dose reductions, which can impact the overall efficacy of the therapy and patient compliance. As a result, patients may seek alternative therapies or choose not to complete the prescribed chemotherapy regimen, hindering overall market growth.

Immunotherapy, though revolutionary in treating cancers like melanoma and lung cancer, comes with a unique set of immune-related adverse events. These adverse effects arise from the immune system's overreaction to cancer treatments, which can lead to inflammation in normal tissues and organs. Targeted therapies, while more precise than traditional chemotherapy, still have specific side effects related to the targeted molecules they affect. These therapies can be highly effective for cancers driven by specific genetic mutations, but side effects related to the inhibition of these molecular targets can limit their use.

Segment Analysis

The global oncology therapy market is segmented based on therapy, application, end-user, and region.

Application:

The breast cancer segment is expected to dominate the oncology therapy market with the highest market share

Breast cancer is the most common cancer in women worldwide. The global burden of breast cancer is substantial, and its increasing prevalence drives the demand for effective oncology therapies. For instance, according to the World Health Organization (WHO), in 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths globally, making it the most common cancer across both developed and developing countries.

The advancements in breast cancer treatments are a major driver of the segment's dominance. Over the last few decades, innovations such as targeted therapies, hormonal therapies, and immunotherapies have dramatically improved survival rates and quality of life for breast cancer patients. For instance, targeted therapies like Trastuzumab (Herceptin) have transformed the treatment of HER2-positive breast cancer, leading to improvements in survival for patients.

Novel product launches by major market players in the field of breast cancer are boosting the segment. For instance, in January 2024, AstraZeneca India Pharma Ltd., a science-led biopharmaceutical company, officially launched Trastuzumab deruxtecan, a therapy tailored for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate (ADC).

Geographical Analysis

North America is expected to hold a significant position in the global oncology therapy market with the highest market share

The oncology therapy market in the North America region is expected to grow owing to the strong presence of major market players, the rising prevalence of cancers, increasing research activities, rising awareness about cancer, rising clinical studies, and well-established healthcare infrastructure. The prevalence of cancer in the United States is continuously rising, which further increases the demand for various oncology therapies. Factors such as aging populations, lifestyle changes, and the prevalence of risk factors like obesity and smoking are driving the demand for improved treatments.

Moreover, the presence of major market players in the region launching various oncology therapies, along with FDA approvals, further accelerates the market growth in the region. For instance, in April 2024, Johnson & Johnson cleared the U.S. Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. With this approval, CARVYKTI becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Additionally, in May 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Competitive Landscape

Top companies in the oncology therapy market include Amgen Inc., AstraZeneca, Bayer AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GSK plc, Eli Lilly and Company, Rigel Pharmaceuticals, Inc., and others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global oncology therapy market report delivers a detailed analysis with 62 key tables, more than 69 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by Application
2.5. Snippet by End-User
2.6. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Rising Prevalence of Cancer
  - 3.1.1.2. Rising Adoption of Combination Therapies
- 3.1.2. Restraints
  - 3.1.2.1. Adverse Effects Associated with Various Oncology Therapies
  - 3.1.2.2. High Cost of Treatment for Oncology Therapy
- 3.1.3. Opportunity
  - 3.1.3.1. Personalized and Precision Oncology
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established Leaders with the Largest Marketing Brand
- 4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
4.4. Porter's Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.10. Pricing Analysis and Price Dynamics

5. Oncology Therapy Market, By Therapy

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 5.1.2. Market Attractiveness Index, By Therapy
5.2. Chemotherapy*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.2.3. Alkylating Agents
- 5.2.4. Antimetabolites
- 5.2.5. Anti-tumor Antibiotics
- 5.2.6. Topoisomerase Inhibitors
- 5.2.7. Others
5.3. Targeted Therapy
- 5.3.1. Monoclonal Antibodies
- 5.3.2. Small Molecule Inhibitors
5.4. Immunotherapy
- 5.4.1. Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
- 5.4.2. CAR-T Cell Therapy
- 5.4.3. Cancer Vaccines
- 5.4.4. Cytokines
- 5.4.5. Others
5.5. Hormonal Therapy
- 5.5.1. Anti-estrogens
- 5.5.2. Aromatase Inhibitors
- 5.5.3. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists/Antagonists
- 5.5.4. Others
5.6. Radiation Therapy
5.7. Others

6. Oncology Therapy Market, By Application

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 6.1.2. Market Attractiveness Index, By Application
6.2. Breast Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Blood Cancer
6.5. Prostate Cancer
6.6. Colorectal Cancer
6.7. Stomach Cancer
6.8. Liver Cancer
6.9. Esophageal Cancer
6.10. Cervical Cancer
6.11. Ovarian Cancer
6.12. Bladder Cancer
6.13. Head and Neck Cancer
6.14. Skin Cancer (Melanoma)
6.15. Pancreatic Cancer
6.16. Kidney Cancer
6.17. Others

7. Oncology Therapy Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cancer Research Centers
7.4. Specialty Clinics
7.5. Others

8. Oncology Therapy Market, By Regional Market Analysis and Growth Opportunities

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.6.1. U.S.
  - 8.2.6.2. Canada
  - 8.2.6.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. UK
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
8.4. Asia-Pacific
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. China
  - 8.4.6.2. India
  - 8.4.6.3. Japan
  - 8.4.6.4. South Korea
  - 8.4.6.5. Rest of Asia-Pacific
8.5. South America
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.6.1. Brazil
  - 8.5.6.2. Argentina
  - 8.5.6.3. Rest of South America
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. Company Profiles

10.1. Amgen Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
  - 10.1.2.1. Product Description
  - 10.1.2.2. Product Key Performance Indicators (KPIs)
  - 10.1.2.3. Historic and Forecasted Product Sales
  - 10.1.2.4. Product Sales Volume
- 10.1.3. Financial Overview
  - 10.1.3.1. Company Revenue
  - 10.1.3.2. Geographical Revenue Shares
  - 10.1.3.3. Revenue Forecasts
- 10.1.4. Key Developments
  - 10.1.4.1. Mergers & Acquisitions
  - 10.1.4.2. Key Product Development Activities
  - 10.1.4.3. Regulatory Approvals, etc.
- 10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. Bayer AG
10.4. Merck & Co., Inc.
10.5. Johnson & Johnson Services, Inc.
10.6. F. Hoffmann-La Roche Ltd
10.7. Novartis AG
10.8. GSK plc
10.9. Eli Lilly and Company
10.10. Rigel Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation

12. Appendix

12.1. About Us and Services
12.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格